A study involving 423 participants analyzed AFB1-albumin adduct levels concerning various metabolic conditions, including diabetes, obesity, central obesity, metabolic syndrome, and non-alcoholic fatty liver disease (NAFLD). Here, ALB is linked to metabolic dysfunction-associated steatotic liver disease.